StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$149.40−7.10 (-4.54%)

Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –

Alnylam Pharmaceuticals price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Alnylam Pharmaceuticals's price to book ratio was 15.8× on Nov 11, 2026, against 102.5× a year earlier. Over the last 5 years it ranged from 5.1× to 475.5×, with a median of 24.4×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202615.8×−74.5
2025Dec 31, 202590.3×−52.1
2022Oct 31, 2022142.4×+115.6
2021Dec 31, 202126.8×+14.4
2020Dec 31, 202012.4×+4.4
2019Dec 31, 20198.0×+3.0
2018Dec 31, 20185.0×−6.1
2017Dec 29, 201711.1×+7.9
2016Dec 30, 20163.2×−2.9
2015Dec 31, 20156.0×−2.2
2014Dec 31, 20148.2×−5.4
2013Dec 31, 201313.7×+8.3
2012Dec 31, 20125.4×+2.7
2011Dec 30, 20112.7×+0.1
2010Dec 31, 20102.6×–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?